Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC.
Heersche N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, Ulas EB, Trooster TMA, de Jonge E, Oomen-de Hoop E, Paats MS, Bahce I, Croes S, Hendriks LEL, van der Wekken AJ, Dingemans AC, Huitema ADR, van Schaik RHN, Mathijssen RHJ, Veerman GDM. Heersche N, et al. Among authors: croes s. J Thorac Oncol. 2024 Nov 29:S1556-0864(24)02488-2. doi: 10.1016/j.jtho.2024.11.025. Online ahead of print. J Thorac Oncol. 2024. PMID: 39617342 Free article.
Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment.
Boosman RJ, Dorlo TPC, de Rouw N, Burgers JA, Dingemans AC, van den Heuvel MM, Hendriks LEL, Biesma B, Aerts JGJV, Croes S, Mathijssen RHJ, Huitema ADR, Ter Heine R. Boosman RJ, et al. Among authors: croes s. Int J Cancer. 2021 Oct 15;149(8):1576-1584. doi: 10.1002/ijc.33721. Epub 2021 Jul 7. Int J Cancer. 2021. PMID: 34181276
Hyperhydration with cisplatin does not influence pemetrexed exposure.
de Rouw N, Derijks HJ, Hilbrands LB, Boosman RJ, Piet B, Koolen SLW, Burgers JA, Dingemans AC, van den Heuvel MM, Hendriks LEL, Aerts JGJV, Croes S, Mathijssen RHJ, Huitema ADR, Burger DM, Biesma B, Ter Heine R. de Rouw N, et al. Among authors: croes s. Br J Clin Pharmacol. 2022 Feb;88(2):871-876. doi: 10.1111/bcp.15031. Epub 2021 Aug 26. Br J Clin Pharmacol. 2022. PMID: 34374116 Free PMC article.
Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.
van Veelen A, Abtahi S, Souverein P, Driessen JHM, Klungel OH, Dingemans AC, van Geel R, de Vries F, Croes S. van Veelen A, et al. Among authors: croes s. Cancer Epidemiol. 2022 Jun;78:102149. doi: 10.1016/j.canep.2022.102149. Epub 2022 Apr 13. Cancer Epidemiol. 2022. PMID: 35429893 Free article. Clinical Trial.
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.
de Rouw N, Boosman RJ, Burgers JA, Huitema ADR, Dingemans AC, Derijks HJ, Burger DM, Piet B, Hendriks LEL, Biesma B, Pruis MA, Dumoulin DW, Croes S, Mathijssen RHJ, van den Heuvel MM, Ter Heine R. de Rouw N, et al. Among authors: croes s. Cancer Chemother Pharmacol. 2023 Jan;91(1):33-42. doi: 10.1007/s00280-022-04489-1. Epub 2022 Nov 21. Cancer Chemother Pharmacol. 2023. PMID: 36413252 Free PMC article. Clinical Trial.
Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma.
Gulikers JL, van Veelen AJ, Sinkiewicz EMJ, de Beer YM, Slikkerveer M, Stolk LML, Tjan-Heijnen VCG, Hendriks LEL, Croes S, van Geel RMJM. Gulikers JL, et al. Among authors: croes s. Biomed Chromatogr. 2023 Jun;37(6):e5628. doi: 10.1002/bmc.5628. Epub 2023 Apr 12. Biomed Chromatogr. 2023. PMID: 36941218
67 results